nodes	percent_of_prediction	percent_of_DWPC	metapath
Asenapine—HTR7—vas deferens—testicular cancer	0.0621	0.364	CbGeAlD
Asenapine—HTR7—vein—testicular cancer	0.0264	0.155	CbGeAlD
Asenapine—HTR2A—vein—testicular cancer	0.0164	0.0964	CbGeAlD
Asenapine—DRD4—testis—testicular cancer	0.00776	0.0455	CbGeAlD
Asenapine—HTR1E—female gonad—testicular cancer	0.00755	0.0443	CbGeAlD
Asenapine—ADRA2C—seminal vesicle—testicular cancer	0.00431	0.0253	CbGeAlD
Asenapine—HRH2—lymph node—testicular cancer	0.00348	0.0204	CbGeAlD
Asenapine—ADRA2A—seminal vesicle—testicular cancer	0.00344	0.0202	CbGeAlD
Asenapine—HTR7—gonad—testicular cancer	0.00339	0.0199	CbGeAlD
Asenapine—HTR2A—embryo—testicular cancer	0.00311	0.0183	CbGeAlD
Asenapine—HTR5A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00271	0.0301	CbGpPWpGaD
Asenapine—ADRA2C—female gonad—testicular cancer	0.00253	0.0148	CbGeAlD
Asenapine—ADRA2A—gonad—testicular cancer	0.00248	0.0146	CbGeAlD
Asenapine—HTR7—testis—testicular cancer	0.00244	0.0143	CbGeAlD
Asenapine—SLC6A4—NRF2 pathway—SLC2A6—testicular cancer	0.00236	0.0262	CbGpPWpGaD
Asenapine—DRD2—testis—testicular cancer	0.00231	0.0135	CbGeAlD
Asenapine—ADRA2C—testis—testicular cancer	0.00224	0.0132	CbGeAlD
Asenapine—HTR2A—gonad—testicular cancer	0.00211	0.0124	CbGeAlD
Asenapine—HTR6—G alpha (s) signalling events—INSL3—testicular cancer	0.0021	0.0233	CbGpPWpGaD
Asenapine—HTR7—G alpha (s) signalling events—INSL3—testicular cancer	0.00209	0.0233	CbGpPWpGaD
Asenapine—HTR2B—lymph node—testicular cancer	0.00207	0.0121	CbGeAlD
Asenapine—HTR5A—GPCR ligand binding—INSL3—testicular cancer	0.00206	0.0229	CbGpPWpGaD
Asenapine—HRH1—female gonad—testicular cancer	0.00206	0.0121	CbGeAlD
Asenapine—ADRA2A—female gonad—testicular cancer	0.00202	0.0118	CbGeAlD
Asenapine—UGT1A4—Phase II conjugation—HPGDS—testicular cancer	0.00184	0.0205	CbGpPWpGaD
Asenapine—HRH1—testis—testicular cancer	0.00182	0.0107	CbGeAlD
Asenapine—DRD1—G alpha (s) signalling events—INSL3—testicular cancer	0.0018	0.0201	CbGpPWpGaD
Asenapine—ADRA2A—testis—testicular cancer	0.00179	0.0105	CbGeAlD
Asenapine—Hypersensitivity—Vinblastine—testicular cancer	0.00173	0.00234	CcSEcCtD
Asenapine—Muscle spasms—Cisplatin—testicular cancer	0.00172	0.00233	CcSEcCtD
Asenapine—Angiopathy—Etoposide—testicular cancer	0.00171	0.00231	CcSEcCtD
Asenapine—Immune system disorder—Etoposide—testicular cancer	0.0017	0.0023	CcSEcCtD
Asenapine—Mediastinal disorder—Etoposide—testicular cancer	0.0017	0.0023	CcSEcCtD
Asenapine—Anaphylactic shock—Ifosfamide—testicular cancer	0.00169	0.00229	CcSEcCtD
Asenapine—Anaphylactoid reaction—Methotrexate—testicular cancer	0.00169	0.00228	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.00168	0.00228	CcSEcCtD
Asenapine—Asthenia—Vinblastine—testicular cancer	0.00168	0.00228	CcSEcCtD
Asenapine—Tremor—Cisplatin—testicular cancer	0.00168	0.00227	CcSEcCtD
Asenapine—Nervous system disorder—Ifosfamide—testicular cancer	0.00166	0.00225	CcSEcCtD
Asenapine—Thrombocytopenia—Ifosfamide—testicular cancer	0.00166	0.00224	CcSEcCtD
Asenapine—Anaemia—Cisplatin—testicular cancer	0.00165	0.00224	CcSEcCtD
Asenapine—Osteoarthritis—Methotrexate—testicular cancer	0.00163	0.00221	CcSEcCtD
Asenapine—Vomiting—Chlorambucil—testicular cancer	0.00163	0.0022	CcSEcCtD
Asenapine—ADRA2C—lymph node—testicular cancer	0.00163	0.00954	CbGeAlD
Asenapine—Increased appetite—Epirubicin—testicular cancer	0.00162	0.0022	CcSEcCtD
Asenapine—Diabetes mellitus—Doxorubicin—testicular cancer	0.00162	0.0022	CcSEcCtD
Asenapine—ADRB1—G alpha (s) signalling events—INSL3—testicular cancer	0.00162	0.018	CbGpPWpGaD
Asenapine—Malaise—Cisplatin—testicular cancer	0.00161	0.00218	CcSEcCtD
Asenapine—Dysgeusia—Etoposide—testicular cancer	0.00161	0.00217	CcSEcCtD
Asenapine—Leukopenia—Cisplatin—testicular cancer	0.0016	0.00217	CcSEcCtD
Asenapine—Dermatitis bullous—Epirubicin—testicular cancer	0.0016	0.00216	CcSEcCtD
Asenapine—Fatigue—Dactinomycin—testicular cancer	0.00159	0.00216	CcSEcCtD
Asenapine—ADRB2—G alpha (s) signalling events—INSL3—testicular cancer	0.00159	0.0176	CbGpPWpGaD
Asenapine—Hypotension—Ifosfamide—testicular cancer	0.00158	0.00214	CcSEcCtD
Asenapine—Anaphylactoid reaction—Epirubicin—testicular cancer	0.00158	0.00213	CcSEcCtD
Asenapine—Muscle spasms—Etoposide—testicular cancer	0.00158	0.00213	CcSEcCtD
Asenapine—CYP2D6—female gonad—testicular cancer	0.00156	0.00917	CbGeAlD
Asenapine—Irritability—Methotrexate—testicular cancer	0.00156	0.00211	CcSEcCtD
Asenapine—Dizziness—Vinblastine—testicular cancer	0.00155	0.0021	CcSEcCtD
Asenapine—Convulsion—Cisplatin—testicular cancer	0.00155	0.0021	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.00154	0.00209	CcSEcCtD
Asenapine—Hyponatraemia—Epirubicin—testicular cancer	0.00153	0.00207	CcSEcCtD
Asenapine—Osteoarthritis—Epirubicin—testicular cancer	0.00153	0.00206	CcSEcCtD
Asenapine—Pain in extremity—Epirubicin—testicular cancer	0.00153	0.00206	CcSEcCtD
Asenapine—HTR2A—testis—testicular cancer	0.00152	0.00893	CbGeAlD
Asenapine—Nausea—Chlorambucil—testicular cancer	0.00152	0.00206	CcSEcCtD
Asenapine—Anxiety—Cisplatin—testicular cancer	0.00152	0.00205	CcSEcCtD
Asenapine—Anaemia—Etoposide—testicular cancer	0.00152	0.00205	CcSEcCtD
Asenapine—Dyspnoea—Ifosfamide—testicular cancer	0.00151	0.00204	CcSEcCtD
Asenapine—Somnolence—Ifosfamide—testicular cancer	0.00151	0.00204	CcSEcCtD
Asenapine—Increased appetite—Doxorubicin—testicular cancer	0.0015	0.00203	CcSEcCtD
Asenapine—Vomiting—Vinblastine—testicular cancer	0.00149	0.00202	CcSEcCtD
Asenapine—Malaise—Etoposide—testicular cancer	0.00148	0.002	CcSEcCtD
Asenapine—Dermatitis bullous—Doxorubicin—testicular cancer	0.00148	0.002	CcSEcCtD
Asenapine—Breast disorder—Methotrexate—testicular cancer	0.00147	0.00199	CcSEcCtD
Asenapine—Headache—Vinblastine—testicular cancer	0.00147	0.00199	CcSEcCtD
Asenapine—Leukopenia—Etoposide—testicular cancer	0.00147	0.00199	CcSEcCtD
Asenapine—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00146	0.00198	CcSEcCtD
Asenapine—HTR1E—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00146	0.0163	CbGpPWpGaD
Asenapine—Fatigue—Ifosfamide—testicular cancer	0.00146	0.00198	CcSEcCtD
Asenapine—Anaphylactic shock—Cisplatin—testicular cancer	0.00146	0.00198	CcSEcCtD
Asenapine—Hypersensitivity—Bleomycin—testicular cancer	0.00146	0.00198	CcSEcCtD
Asenapine—Anaphylactoid reaction—Doxorubicin—testicular cancer	0.00146	0.00197	CcSEcCtD
Asenapine—Constipation—Ifosfamide—testicular cancer	0.00145	0.00196	CcSEcCtD
Asenapine—Loss of consciousness—Etoposide—testicular cancer	0.00144	0.00195	CcSEcCtD
Asenapine—Nervous system disorder—Cisplatin—testicular cancer	0.00143	0.00194	CcSEcCtD
Asenapine—Thrombocytopenia—Cisplatin—testicular cancer	0.00143	0.00193	CcSEcCtD
Asenapine—Tachycardia—Cisplatin—testicular cancer	0.00143	0.00193	CcSEcCtD
Asenapine—Asthenia—Bleomycin—testicular cancer	0.00142	0.00192	CcSEcCtD
Asenapine—Convulsion—Etoposide—testicular cancer	0.00142	0.00192	CcSEcCtD
Asenapine—Hyponatraemia—Doxorubicin—testicular cancer	0.00142	0.00192	CcSEcCtD
Asenapine—Hypertension—Etoposide—testicular cancer	0.00142	0.00191	CcSEcCtD
Asenapine—Pain in extremity—Doxorubicin—testicular cancer	0.00141	0.00191	CcSEcCtD
Asenapine—Osteoarthritis—Doxorubicin—testicular cancer	0.00141	0.00191	CcSEcCtD
Asenapine—Nausea—Vinblastine—testicular cancer	0.00139	0.00189	CcSEcCtD
Asenapine—Orthostatic hypotension—Epirubicin—testicular cancer	0.00139	0.00189	CcSEcCtD
Asenapine—CYP2D6—testis—testicular cancer	0.00139	0.00813	CbGeAlD
Asenapine—Breast disorder—Epirubicin—testicular cancer	0.00138	0.00187	CcSEcCtD
Asenapine—Hypotension—Cisplatin—testicular cancer	0.00137	0.00185	CcSEcCtD
Asenapine—Hypersensitivity—Dactinomycin—testicular cancer	0.00136	0.00184	CcSEcCtD
Asenapine—Abdominal discomfort—Methotrexate—testicular cancer	0.00135	0.00183	CcSEcCtD
Asenapine—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.00135	0.00182	CcSEcCtD
Asenapine—Anaphylactic shock—Etoposide—testicular cancer	0.00134	0.00181	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.00133	0.0018	CcSEcCtD
Asenapine—Asthenia—Dactinomycin—testicular cancer	0.00133	0.00179	CcSEcCtD
Asenapine—HRH1—lymph node—testicular cancer	0.00132	0.00775	CbGeAlD
Asenapine—Dysphagia—Epirubicin—testicular cancer	0.00132	0.00178	CcSEcCtD
Asenapine—Neutropenia—Methotrexate—testicular cancer	0.00132	0.00178	CcSEcCtD
Asenapine—Thrombocytopenia—Etoposide—testicular cancer	0.00131	0.00177	CcSEcCtD
Asenapine—Tachycardia—Etoposide—testicular cancer	0.00131	0.00177	CcSEcCtD
Asenapine—HRH2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.0013	0.0145	CbGpPWpGaD
Asenapine—Dyspnoea—Cisplatin—testicular cancer	0.0013	0.00176	CcSEcCtD
Asenapine—ADRA2A—lymph node—testicular cancer	0.0013	0.00761	CbGeAlD
Asenapine—Orthostatic hypotension—Doxorubicin—testicular cancer	0.00129	0.00174	CcSEcCtD
Asenapine—Breast disorder—Doxorubicin—testicular cancer	0.00128	0.00173	CcSEcCtD
Asenapine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00126	0.00171	CcSEcCtD
Asenapine—Vomiting—Bleomycin—testicular cancer	0.00126	0.0017	CcSEcCtD
Asenapine—Depression—Methotrexate—testicular cancer	0.00125	0.00169	CcSEcCtD
Asenapine—Hypotension—Etoposide—testicular cancer	0.00125	0.00169	CcSEcCtD
Asenapine—Rash—Bleomycin—testicular cancer	0.00125	0.00169	CcSEcCtD
Asenapine—Dermatitis—Bleomycin—testicular cancer	0.00125	0.00169	CcSEcCtD
Asenapine—Hypersensitivity—Ifosfamide—testicular cancer	0.00125	0.00169	CcSEcCtD
Asenapine—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.00125	0.00168	CcSEcCtD
Asenapine—Neutropenia—Epirubicin—testicular cancer	0.00123	0.00167	CcSEcCtD
Asenapine—Stomatitis—Methotrexate—testicular cancer	0.00123	0.00166	CcSEcCtD
Asenapine—Dysphagia—Doxorubicin—testicular cancer	0.00122	0.00165	CcSEcCtD
Asenapine—Asthenia—Ifosfamide—testicular cancer	0.00122	0.00164	CcSEcCtD
Asenapine—Weight increased—Epirubicin—testicular cancer	0.0012	0.00162	CcSEcCtD
Asenapine—Dyspnoea—Etoposide—testicular cancer	0.00119	0.00161	CcSEcCtD
Asenapine—Hyperglycaemia—Epirubicin—testicular cancer	0.00119	0.00161	CcSEcCtD
Asenapine—Somnolence—Etoposide—testicular cancer	0.00119	0.00161	CcSEcCtD
Asenapine—Hepatobiliary disease—Methotrexate—testicular cancer	0.00119	0.00161	CcSEcCtD
Asenapine—Nausea—Bleomycin—testicular cancer	0.00118	0.00159	CcSEcCtD
Asenapine—Vomiting—Dactinomycin—testicular cancer	0.00118	0.00159	CcSEcCtD
Asenapine—Agranulocytosis—Methotrexate—testicular cancer	0.00117	0.00159	CcSEcCtD
Asenapine—Rash—Dactinomycin—testicular cancer	0.00117	0.00158	CcSEcCtD
Asenapine—HTR5A—GPCR downstream signaling—INSL3—testicular cancer	0.00117	0.013	CbGpPWpGaD
Asenapine—Gastrointestinal disorder—Etoposide—testicular cancer	0.00116	0.00156	CcSEcCtD
Asenapine—Fatigue—Etoposide—testicular cancer	0.00115	0.00156	CcSEcCtD
Asenapine—Stomatitis—Epirubicin—testicular cancer	0.00115	0.00155	CcSEcCtD
Asenapine—Constipation—Etoposide—testicular cancer	0.00114	0.00155	CcSEcCtD
Asenapine—Neutropenia—Doxorubicin—testicular cancer	0.00114	0.00154	CcSEcCtD
Asenapine—Dizziness—Ifosfamide—testicular cancer	0.00112	0.00152	CcSEcCtD
Asenapine—HTR1E—GPCR ligand binding—INSL3—testicular cancer	0.00111	0.0124	CbGpPWpGaD
Asenapine—Hepatobiliary disease—Epirubicin—testicular cancer	0.00111	0.0015	CcSEcCtD
Asenapine—Weight increased—Doxorubicin—testicular cancer	0.00111	0.0015	CcSEcCtD
Asenapine—Hyperglycaemia—Doxorubicin—testicular cancer	0.0011	0.00149	CcSEcCtD
Asenapine—Nausea—Dactinomycin—testicular cancer	0.0011	0.00149	CcSEcCtD
Asenapine—Agranulocytosis—Epirubicin—testicular cancer	0.0011	0.00148	CcSEcCtD
Asenapine—UGT1A4—Biological oxidations—HPGDS—testicular cancer	0.00108	0.012	CbGpPWpGaD
Asenapine—Vomiting—Ifosfamide—testicular cancer	0.00108	0.00146	CcSEcCtD
Asenapine—Hypersensitivity—Cisplatin—testicular cancer	0.00108	0.00146	CcSEcCtD
Asenapine—Rash—Ifosfamide—testicular cancer	0.00107	0.00144	CcSEcCtD
Asenapine—Dermatitis—Ifosfamide—testicular cancer	0.00107	0.00144	CcSEcCtD
Asenapine—Stomatitis—Doxorubicin—testicular cancer	0.00106	0.00143	CcSEcCtD
Asenapine—HTR5A—Signaling by GPCR—INSL3—testicular cancer	0.00106	0.0118	CbGpPWpGaD
Asenapine—Eye disorder—Methotrexate—testicular cancer	0.00105	0.00143	CcSEcCtD
Asenapine—Asthenia—Cisplatin—testicular cancer	0.00105	0.00142	CcSEcCtD
Asenapine—Cardiac disorder—Methotrexate—testicular cancer	0.00105	0.00142	CcSEcCtD
Asenapine—Oedema peripheral—Epirubicin—testicular cancer	0.00104	0.00141	CcSEcCtD
Asenapine—Connective tissue disorder—Epirubicin—testicular cancer	0.00104	0.0014	CcSEcCtD
Asenapine—Hepatobiliary disease—Doxorubicin—testicular cancer	0.00103	0.00139	CcSEcCtD
Asenapine—Angiopathy—Methotrexate—testicular cancer	0.00102	0.00138	CcSEcCtD
Asenapine—Immune system disorder—Methotrexate—testicular cancer	0.00102	0.00138	CcSEcCtD
Asenapine—Mediastinal disorder—Methotrexate—testicular cancer	0.00102	0.00138	CcSEcCtD
Asenapine—Agranulocytosis—Doxorubicin—testicular cancer	0.00102	0.00137	CcSEcCtD
Asenapine—Nausea—Ifosfamide—testicular cancer	0.00101	0.00136	CcSEcCtD
Asenapine—HTR6—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000999	0.0111	CbGpPWpGaD
Asenapine—HTR7—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000998	0.0111	CbGpPWpGaD
Asenapine—HRH2—GPCR ligand binding—INSL3—testicular cancer	0.000992	0.011	CbGpPWpGaD
Asenapine—HTR1D—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000991	0.011	CbGpPWpGaD
Asenapine—Mental disorder—Methotrexate—testicular cancer	0.000989	0.00134	CcSEcCtD
Asenapine—Eye disorder—Epirubicin—testicular cancer	0.000987	0.00133	CcSEcCtD
Asenapine—Hypersensitivity—Etoposide—testicular cancer	0.000986	0.00133	CcSEcCtD
Asenapine—Malnutrition—Methotrexate—testicular cancer	0.000982	0.00133	CcSEcCtD
Asenapine—Cardiac disorder—Epirubicin—testicular cancer	0.00098	0.00133	CcSEcCtD
Asenapine—HTR1B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000971	0.0108	CbGpPWpGaD
Asenapine—Oedema peripheral—Doxorubicin—testicular cancer	0.000963	0.0013	CcSEcCtD
Asenapine—Dysgeusia—Methotrexate—testicular cancer	0.000962	0.0013	CcSEcCtD
Asenapine—Asthenia—Etoposide—testicular cancer	0.00096	0.0013	CcSEcCtD
Asenapine—Connective tissue disorder—Doxorubicin—testicular cancer	0.00096	0.0013	CcSEcCtD
Asenapine—Angiopathy—Epirubicin—testicular cancer	0.000958	0.0013	CcSEcCtD
Asenapine—DRD4—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000955	0.0106	CbGpPWpGaD
Asenapine—Immune system disorder—Epirubicin—testicular cancer	0.000954	0.00129	CcSEcCtD
Asenapine—Mediastinal disorder—Epirubicin—testicular cancer	0.000952	0.00129	CcSEcCtD
Asenapine—Vomiting—Cisplatin—testicular cancer	0.000929	0.00126	CcSEcCtD
Asenapine—Mental disorder—Epirubicin—testicular cancer	0.000925	0.00125	CcSEcCtD
Asenapine—Rash—Cisplatin—testicular cancer	0.000921	0.00125	CcSEcCtD
Asenapine—Dermatitis—Cisplatin—testicular cancer	0.00092	0.00124	CcSEcCtD
Asenapine—Malnutrition—Epirubicin—testicular cancer	0.000919	0.00124	CcSEcCtD
Asenapine—Eye disorder—Doxorubicin—testicular cancer	0.000913	0.00123	CcSEcCtD
Asenapine—HTR2B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000912	0.0101	CbGpPWpGaD
Asenapine—Anaemia—Methotrexate—testicular cancer	0.000908	0.00123	CcSEcCtD
Asenapine—Cardiac disorder—Doxorubicin—testicular cancer	0.000907	0.00123	CcSEcCtD
Asenapine—Dysgeusia—Epirubicin—testicular cancer	0.0009	0.00122	CcSEcCtD
Asenapine—Angiopathy—Doxorubicin—testicular cancer	0.000887	0.0012	CcSEcCtD
Asenapine—Malaise—Methotrexate—testicular cancer	0.000886	0.0012	CcSEcCtD
Asenapine—Dizziness—Etoposide—testicular cancer	0.000885	0.0012	CcSEcCtD
Asenapine—Muscle spasms—Epirubicin—testicular cancer	0.000884	0.0012	CcSEcCtD
Asenapine—Immune system disorder—Doxorubicin—testicular cancer	0.000883	0.00119	CcSEcCtD
Asenapine—Mediastinal disorder—Doxorubicin—testicular cancer	0.000881	0.00119	CcSEcCtD
Asenapine—Leukopenia—Methotrexate—testicular cancer	0.000879	0.00119	CcSEcCtD
Asenapine—Nausea—Cisplatin—testicular cancer	0.000868	0.00117	CcSEcCtD
Asenapine—DRD1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00086	0.00956	CbGpPWpGaD
Asenapine—Mental disorder—Doxorubicin—testicular cancer	0.000856	0.00116	CcSEcCtD
Asenapine—Convulsion—Methotrexate—testicular cancer	0.000851	0.00115	CcSEcCtD
Asenapine—Vomiting—Etoposide—testicular cancer	0.000851	0.00115	CcSEcCtD
Asenapine—Malnutrition—Doxorubicin—testicular cancer	0.000851	0.00115	CcSEcCtD
Asenapine—Anaemia—Epirubicin—testicular cancer	0.00085	0.00115	CcSEcCtD
Asenapine—DRD3—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000849	0.00944	CbGpPWpGaD
Asenapine—Agitation—Epirubicin—testicular cancer	0.000845	0.00114	CcSEcCtD
Asenapine—Rash—Etoposide—testicular cancer	0.000844	0.00114	CcSEcCtD
Asenapine—Dermatitis—Etoposide—testicular cancer	0.000843	0.00114	CcSEcCtD
Asenapine—Headache—Etoposide—testicular cancer	0.000839	0.00113	CcSEcCtD
Asenapine—Arthralgia—Methotrexate—testicular cancer	0.000836	0.00113	CcSEcCtD
Asenapine—Dysgeusia—Doxorubicin—testicular cancer	0.000833	0.00113	CcSEcCtD
Asenapine—Malaise—Epirubicin—testicular cancer	0.000829	0.00112	CcSEcCtD
Asenapine—Syncope—Epirubicin—testicular cancer	0.000824	0.00111	CcSEcCtD
Asenapine—Leukopenia—Epirubicin—testicular cancer	0.000823	0.00111	CcSEcCtD
Asenapine—Muscle spasms—Doxorubicin—testicular cancer	0.000818	0.00111	CcSEcCtD
Asenapine—Loss of consciousness—Epirubicin—testicular cancer	0.000808	0.00109	CcSEcCtD
Asenapine—Anaphylactic shock—Methotrexate—testicular cancer	0.000802	0.00108	CcSEcCtD
Asenapine—Convulsion—Epirubicin—testicular cancer	0.000797	0.00108	CcSEcCtD
Asenapine—Nausea—Etoposide—testicular cancer	0.000795	0.00108	CcSEcCtD
Asenapine—Hypertension—Epirubicin—testicular cancer	0.000794	0.00107	CcSEcCtD
Asenapine—Nervous system disorder—Methotrexate—testicular cancer	0.000786	0.00106	CcSEcCtD
Asenapine—Anaemia—Doxorubicin—testicular cancer	0.000786	0.00106	CcSEcCtD
Asenapine—Thrombocytopenia—Methotrexate—testicular cancer	0.000785	0.00106	CcSEcCtD
Asenapine—Arthralgia—Epirubicin—testicular cancer	0.000783	0.00106	CcSEcCtD
Asenapine—Agitation—Doxorubicin—testicular cancer	0.000782	0.00106	CcSEcCtD
Asenapine—Anxiety—Epirubicin—testicular cancer	0.00078	0.00105	CcSEcCtD
Asenapine—ADRB1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000773	0.0086	CbGpPWpGaD
Asenapine—Malaise—Doxorubicin—testicular cancer	0.000767	0.00104	CcSEcCtD
Asenapine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000766	0.00852	CbGpPWpGaD
Asenapine—Dry mouth—Epirubicin—testicular cancer	0.000765	0.00104	CcSEcCtD
Asenapine—Syncope—Doxorubicin—testicular cancer	0.000763	0.00103	CcSEcCtD
Asenapine—Leukopenia—Doxorubicin—testicular cancer	0.000761	0.00103	CcSEcCtD
Asenapine—HTR6—GPCR ligand binding—INSL3—testicular cancer	0.000761	0.00846	CbGpPWpGaD
Asenapine—HTR7—GPCR ligand binding—INSL3—testicular cancer	0.00076	0.00845	CbGpPWpGaD
Asenapine—ADRB2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000756	0.00841	CbGpPWpGaD
Asenapine—HTR1D—GPCR ligand binding—INSL3—testicular cancer	0.000755	0.0084	CbGpPWpGaD
Asenapine—Anaphylactic shock—Epirubicin—testicular cancer	0.00075	0.00101	CcSEcCtD
Asenapine—Hypotension—Methotrexate—testicular cancer	0.000749	0.00101	CcSEcCtD
Asenapine—Loss of consciousness—Doxorubicin—testicular cancer	0.000748	0.00101	CcSEcCtD
Asenapine—HTR1A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.00074	0.00822	CbGpPWpGaD
Asenapine—HTR1B—GPCR ligand binding—INSL3—testicular cancer	0.000739	0.00822	CbGpPWpGaD
Asenapine—Shock—Epirubicin—testicular cancer	0.000738	0.000998	CcSEcCtD
Asenapine—Convulsion—Doxorubicin—testicular cancer	0.000737	0.000997	CcSEcCtD
Asenapine—Nervous system disorder—Epirubicin—testicular cancer	0.000736	0.000995	CcSEcCtD
Asenapine—HTR2C—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000736	0.00818	CbGpPWpGaD
Asenapine—Thrombocytopenia—Epirubicin—testicular cancer	0.000735	0.000993	CcSEcCtD
Asenapine—Hypertension—Doxorubicin—testicular cancer	0.000734	0.000993	CcSEcCtD
Asenapine—Tachycardia—Epirubicin—testicular cancer	0.000732	0.00099	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.00073	0.000988	CcSEcCtD
Asenapine—DRD4—GPCR ligand binding—INSL3—testicular cancer	0.000727	0.00809	CbGpPWpGaD
Asenapine—Insomnia—Methotrexate—testicular cancer	0.000725	0.000981	CcSEcCtD
Asenapine—Arthralgia—Doxorubicin—testicular cancer	0.000724	0.000979	CcSEcCtD
Asenapine—Anxiety—Doxorubicin—testicular cancer	0.000722	0.000976	CcSEcCtD
Asenapine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000716	0.00796	CbGpPWpGaD
Asenapine—Dyspnoea—Methotrexate—testicular cancer	0.000715	0.000967	CcSEcCtD
Asenapine—Somnolence—Methotrexate—testicular cancer	0.000713	0.000964	CcSEcCtD
Asenapine—Dry mouth—Doxorubicin—testicular cancer	0.000708	0.000958	CcSEcCtD
Asenapine—Dyspepsia—Methotrexate—testicular cancer	0.000706	0.000954	CcSEcCtD
Asenapine—Hypotension—Epirubicin—testicular cancer	0.000701	0.000948	CcSEcCtD
Asenapine—HTR2B—GPCR ligand binding—INSL3—testicular cancer	0.000694	0.00772	CbGpPWpGaD
Asenapine—Anaphylactic shock—Doxorubicin—testicular cancer	0.000694	0.000939	CcSEcCtD
Asenapine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000692	0.000936	CcSEcCtD
Asenapine—Fatigue—Methotrexate—testicular cancer	0.000691	0.000935	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000684	0.000924	CcSEcCtD
Asenapine—Shock—Doxorubicin—testicular cancer	0.000683	0.000924	CcSEcCtD
Asenapine—Nervous system disorder—Doxorubicin—testicular cancer	0.000681	0.000921	CcSEcCtD
Asenapine—Thrombocytopenia—Doxorubicin—testicular cancer	0.00068	0.000919	CcSEcCtD
Asenapine—Insomnia—Epirubicin—testicular cancer	0.000679	0.000918	CcSEcCtD
Asenapine—Tachycardia—Doxorubicin—testicular cancer	0.000678	0.000916	CcSEcCtD
Asenapine—Dyspnoea—Epirubicin—testicular cancer	0.000669	0.000905	CcSEcCtD
Asenapine—ADRA1A—AMPK Signaling—STK11—testicular cancer	0.000667	0.00742	CbGpPWpGaD
Asenapine—Somnolence—Epirubicin—testicular cancer	0.000667	0.000902	CcSEcCtD
Asenapine—Dyspepsia—Epirubicin—testicular cancer	0.00066	0.000893	CcSEcCtD
Asenapine—DRD1—GPCR ligand binding—INSL3—testicular cancer	0.000655	0.00728	CbGpPWpGaD
Asenapine—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000652	0.00725	CbGpPWpGaD
Asenapine—DRD2—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000649	0.00722	CbGpPWpGaD
Asenapine—Hypotension—Doxorubicin—testicular cancer	0.000649	0.000877	CcSEcCtD
Asenapine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000648	0.000876	CcSEcCtD
Asenapine—Fatigue—Epirubicin—testicular cancer	0.000647	0.000875	CcSEcCtD
Asenapine—DRD3—GPCR ligand binding—INSL3—testicular cancer	0.000646	0.00719	CbGpPWpGaD
Asenapine—Constipation—Epirubicin—testicular cancer	0.000642	0.000868	CcSEcCtD
Asenapine—HTR2A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000639	0.0071	CbGpPWpGaD
Asenapine—HRH1—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000638	0.00709	CbGpPWpGaD
Asenapine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000632	0.000855	CcSEcCtD
Asenapine—HTR1E—GPCR downstream signaling—INSL3—testicular cancer	0.000629	0.007	CbGpPWpGaD
Asenapine—Insomnia—Doxorubicin—testicular cancer	0.000628	0.000849	CcSEcCtD
Asenapine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000626	0.00696	CbGpPWpGaD
Asenapine—HTR5A—Signaling Pathways—INSL3—testicular cancer	0.000625	0.00695	CbGpPWpGaD
Asenapine—Dyspnoea—Doxorubicin—testicular cancer	0.000619	0.000837	CcSEcCtD
Asenapine—Somnolence—Doxorubicin—testicular cancer	0.000617	0.000835	CcSEcCtD
Asenapine—Dyspepsia—Doxorubicin—testicular cancer	0.000611	0.000826	CcSEcCtD
Asenapine—CYP1A2—Arachidonic acid metabolism—HPGDS—testicular cancer	0.00061	0.00678	CbGpPWpGaD
Asenapine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000599	0.00081	CcSEcCtD
Asenapine—Fatigue—Doxorubicin—testicular cancer	0.000599	0.000809	CcSEcCtD
Asenapine—Constipation—Doxorubicin—testicular cancer	0.000594	0.000803	CcSEcCtD
Asenapine—Hypersensitivity—Methotrexate—testicular cancer	0.000591	0.000799	CcSEcCtD
Asenapine—ADRB1—GPCR ligand binding—INSL3—testicular cancer	0.000589	0.00655	CbGpPWpGaD
Asenapine—ADRA2B—GPCR ligand binding—INSL3—testicular cancer	0.000583	0.00649	CbGpPWpGaD
Asenapine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—INSL3—testicular cancer	0.000581	0.00646	CbGpPWpGaD
Asenapine—ADRB2—GPCR ligand binding—INSL3—testicular cancer	0.000576	0.0064	CbGpPWpGaD
Asenapine—Asthenia—Methotrexate—testicular cancer	0.000575	0.000778	CcSEcCtD
Asenapine—HTR1E—Signaling by GPCR—INSL3—testicular cancer	0.000572	0.00636	CbGpPWpGaD
Asenapine—HTR1A—GPCR ligand binding—INSL3—testicular cancer	0.000563	0.00626	CbGpPWpGaD
Asenapine—HRH2—GPCR downstream signaling—INSL3—testicular cancer	0.000561	0.00623	CbGpPWpGaD
Asenapine—HTR2C—GPCR ligand binding—INSL3—testicular cancer	0.00056	0.00623	CbGpPWpGaD
Asenapine—Hypersensitivity—Epirubicin—testicular cancer	0.000553	0.000747	CcSEcCtD
Asenapine—ADRA2C—Integration of energy metabolism—STK11—testicular cancer	0.00055	0.00611	CbGpPWpGaD
Asenapine—ADRA2C—GPCR ligand binding—INSL3—testicular cancer	0.000545	0.00606	CbGpPWpGaD
Asenapine—Asthenia—Epirubicin—testicular cancer	0.000538	0.000728	CcSEcCtD
Asenapine—Dizziness—Methotrexate—testicular cancer	0.00053	0.000717	CcSEcCtD
Asenapine—Hypersensitivity—Doxorubicin—testicular cancer	0.000511	0.000692	CcSEcCtD
Asenapine—Vomiting—Methotrexate—testicular cancer	0.00051	0.000689	CcSEcCtD
Asenapine—HRH2—Signaling by GPCR—INSL3—testicular cancer	0.000509	0.00566	CbGpPWpGaD
Asenapine—Rash—Methotrexate—testicular cancer	0.000506	0.000684	CcSEcCtD
Asenapine—Dermatitis—Methotrexate—testicular cancer	0.000505	0.000683	CcSEcCtD
Asenapine—Headache—Methotrexate—testicular cancer	0.000502	0.000679	CcSEcCtD
Asenapine—Asthenia—Doxorubicin—testicular cancer	0.000498	0.000674	CcSEcCtD
Asenapine—Dizziness—Epirubicin—testicular cancer	0.000496	0.000671	CcSEcCtD
Asenapine—DRD2—GPCR ligand binding—INSL3—testicular cancer	0.000494	0.0055	CbGpPWpGaD
Asenapine—HTR2A—GPCR ligand binding—INSL3—testicular cancer	0.000487	0.00541	CbGpPWpGaD
Asenapine—HRH1—GPCR ligand binding—INSL3—testicular cancer	0.000485	0.0054	CbGpPWpGaD
Asenapine—Vomiting—Epirubicin—testicular cancer	0.000477	0.000645	CcSEcCtD
Asenapine—ADRA1A—GPCR ligand binding—INSL3—testicular cancer	0.000476	0.0053	CbGpPWpGaD
Asenapine—Nausea—Methotrexate—testicular cancer	0.000476	0.000644	CcSEcCtD
Asenapine—Rash—Epirubicin—testicular cancer	0.000473	0.00064	CcSEcCtD
Asenapine—Dermatitis—Epirubicin—testicular cancer	0.000473	0.000639	CcSEcCtD
Asenapine—Headache—Epirubicin—testicular cancer	0.00047	0.000636	CcSEcCtD
Asenapine—Dizziness—Doxorubicin—testicular cancer	0.000459	0.000621	CcSEcCtD
Asenapine—ADRA2A—Integration of energy metabolism—STK11—testicular cancer	0.000447	0.00497	CbGpPWpGaD
Asenapine—Nausea—Epirubicin—testicular cancer	0.000446	0.000603	CcSEcCtD
Asenapine—ADRA2A—GPCR ligand binding—INSL3—testicular cancer	0.000443	0.00492	CbGpPWpGaD
Asenapine—Vomiting—Doxorubicin—testicular cancer	0.000441	0.000597	CcSEcCtD
Asenapine—Rash—Doxorubicin—testicular cancer	0.000438	0.000592	CcSEcCtD
Asenapine—Dermatitis—Doxorubicin—testicular cancer	0.000437	0.000591	CcSEcCtD
Asenapine—Headache—Doxorubicin—testicular cancer	0.000435	0.000588	CcSEcCtD
Asenapine—HTR6—GPCR downstream signaling—INSL3—testicular cancer	0.00043	0.00478	CbGpPWpGaD
Asenapine—HTR7—GPCR downstream signaling—INSL3—testicular cancer	0.000429	0.00478	CbGpPWpGaD
Asenapine—HTR1D—GPCR downstream signaling—INSL3—testicular cancer	0.000427	0.00474	CbGpPWpGaD
Asenapine—HTR1B—GPCR downstream signaling—INSL3—testicular cancer	0.000418	0.00465	CbGpPWpGaD
Asenapine—Nausea—Doxorubicin—testicular cancer	0.000412	0.000558	CcSEcCtD
Asenapine—DRD4—GPCR downstream signaling—INSL3—testicular cancer	0.000411	0.00457	CbGpPWpGaD
Asenapine—HTR2B—GPCR downstream signaling—INSL3—testicular cancer	0.000392	0.00436	CbGpPWpGaD
Asenapine—HTR6—Signaling by GPCR—INSL3—testicular cancer	0.00039	0.00434	CbGpPWpGaD
Asenapine—HTR7—Signaling by GPCR—INSL3—testicular cancer	0.00039	0.00434	CbGpPWpGaD
Asenapine—CYP1A2—Phase II conjugation—HPGDS—testicular cancer	0.000388	0.00431	CbGpPWpGaD
Asenapine—HTR1D—Signaling by GPCR—INSL3—testicular cancer	0.000387	0.00431	CbGpPWpGaD
Asenapine—HTR1B—Signaling by GPCR—INSL3—testicular cancer	0.000379	0.00422	CbGpPWpGaD
Asenapine—DRD4—Signaling by GPCR—INSL3—testicular cancer	0.000373	0.00415	CbGpPWpGaD
Asenapine—DRD1—GPCR downstream signaling—INSL3—testicular cancer	0.00037	0.00412	CbGpPWpGaD
Asenapine—DRD3—GPCR downstream signaling—INSL3—testicular cancer	0.000365	0.00406	CbGpPWpGaD
Asenapine—HTR2B—Signaling by GPCR—INSL3—testicular cancer	0.000356	0.00396	CbGpPWpGaD
Asenapine—HTR1E—Signaling Pathways—INSL3—testicular cancer	0.000338	0.00375	CbGpPWpGaD
Asenapine—DRD1—Signaling by GPCR—INSL3—testicular cancer	0.000336	0.00374	CbGpPWpGaD
Asenapine—ADRB1—GPCR downstream signaling—INSL3—testicular cancer	0.000333	0.0037	CbGpPWpGaD
Asenapine—DRD3—Signaling by GPCR—INSL3—testicular cancer	0.000332	0.00369	CbGpPWpGaD
Asenapine—ADRA2B—GPCR downstream signaling—INSL3—testicular cancer	0.00033	0.00367	CbGpPWpGaD
Asenapine—ADRB2—GPCR downstream signaling—INSL3—testicular cancer	0.000325	0.00362	CbGpPWpGaD
Asenapine—HTR1A—GPCR downstream signaling—INSL3—testicular cancer	0.000318	0.00354	CbGpPWpGaD
Asenapine—HTR2C—GPCR downstream signaling—INSL3—testicular cancer	0.000317	0.00352	CbGpPWpGaD
Asenapine—ADRA2C—GPCR downstream signaling—INSL3—testicular cancer	0.000308	0.00342	CbGpPWpGaD
Asenapine—ADRB1—Signaling by GPCR—INSL3—testicular cancer	0.000302	0.00336	CbGpPWpGaD
Asenapine—HRH2—Signaling Pathways—INSL3—testicular cancer	0.000301	0.00334	CbGpPWpGaD
Asenapine—ADRA2B—Signaling by GPCR—INSL3—testicular cancer	0.000299	0.00333	CbGpPWpGaD
Asenapine—ADRB2—Signaling by GPCR—INSL3—testicular cancer	0.000296	0.00329	CbGpPWpGaD
Asenapine—HTR1A—Signaling by GPCR—INSL3—testicular cancer	0.000289	0.00321	CbGpPWpGaD
Asenapine—HTR2C—Signaling by GPCR—INSL3—testicular cancer	0.000288	0.0032	CbGpPWpGaD
Asenapine—ADRA2C—Signaling by GPCR—INSL3—testicular cancer	0.00028	0.00311	CbGpPWpGaD
Asenapine—DRD2—GPCR downstream signaling—INSL3—testicular cancer	0.000279	0.00311	CbGpPWpGaD
Asenapine—HTR2A—GPCR downstream signaling—INSL3—testicular cancer	0.000275	0.00306	CbGpPWpGaD
Asenapine—HRH1—GPCR downstream signaling—INSL3—testicular cancer	0.000274	0.00305	CbGpPWpGaD
Asenapine—ADRA1A—GPCR downstream signaling—INSL3—testicular cancer	0.000269	0.00299	CbGpPWpGaD
Asenapine—CYP2D6—Biological oxidations—HPGDS—testicular cancer	0.000268	0.00298	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—INSL3—testicular cancer	0.000254	0.00282	CbGpPWpGaD
Asenapine—ADRA2A—GPCR downstream signaling—INSL3—testicular cancer	0.00025	0.00278	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—INSL3—testicular cancer	0.00025	0.00278	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—INSL3—testicular cancer	0.000249	0.00277	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—INSL3—testicular cancer	0.000244	0.00272	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—INSL3—testicular cancer	0.000231	0.00256	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—INSL3—testicular cancer	0.00023	0.00256	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—INSL3—testicular cancer	0.000229	0.00255	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—INSL3—testicular cancer	0.000227	0.00253	CbGpPWpGaD
Asenapine—CYP1A2—Biological oxidations—HPGDS—testicular cancer	0.000227	0.00252	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—INSL3—testicular cancer	0.000224	0.00249	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—INSL3—testicular cancer	0.000221	0.00245	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—INSL3—testicular cancer	0.000211	0.00234	CbGpPWpGaD
Asenapine—HTR5A—Signaling Pathways—H2AFZ—testicular cancer	0.0002	0.00223	CbGpPWpGaD
Asenapine—HTR5A—Signaling Pathways—STK11—testicular cancer	0.000199	0.00221	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—INSL3—testicular cancer	0.000199	0.00221	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—INSL3—testicular cancer	0.000196	0.00218	CbGpPWpGaD
Asenapine—UGT1A4—Metabolism—HPGDS—testicular cancer	0.000184	0.00205	CbGpPWpGaD
Asenapine—HTR5A—Signaling Pathways—KITLG—testicular cancer	0.000184	0.00205	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—INSL3—testicular cancer	0.000178	0.00198	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—INSL3—testicular cancer	0.000177	0.00197	CbGpPWpGaD
Asenapine—CYP3A4—Biological oxidations—HPGDS—testicular cancer	0.000175	0.00195	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—INSL3—testicular cancer	0.000175	0.00194	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—INSL3—testicular cancer	0.000171	0.0019	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—INSL3—testicular cancer	0.00017	0.00189	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—INSL3—testicular cancer	0.000165	0.00184	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—INSL3—testicular cancer	0.00015	0.00167	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—INSL3—testicular cancer	0.000147	0.00164	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—INSL3—testicular cancer	0.000147	0.00164	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—INSL3—testicular cancer	0.000144	0.00161	CbGpPWpGaD
Asenapine—HTR5A—Signaling Pathways—FGFR3—testicular cancer	0.000137	0.00152	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—INSL3—testicular cancer	0.000134	0.00149	CbGpPWpGaD
Asenapine—UGT1A4—Metabolism—STK11—testicular cancer	0.000134	0.00149	CbGpPWpGaD
Asenapine—HTR5A—Signaling Pathways—KIT—testicular cancer	0.000126	0.0014	CbGpPWpGaD
Asenapine—HTR1E—Signaling Pathways—H2AFZ—testicular cancer	0.000108	0.0012	CbGpPWpGaD
Asenapine—HTR1E—Signaling Pathways—STK11—testicular cancer	0.000107	0.00119	CbGpPWpGaD
Asenapine—HTR1E—Signaling Pathways—KITLG—testicular cancer	9.94e-05	0.00111	CbGpPWpGaD
Asenapine—HRH2—Signaling Pathways—H2AFZ—testicular cancer	9.63e-05	0.00107	CbGpPWpGaD
Asenapine—HRH2—Signaling Pathways—STK11—testicular cancer	9.57e-05	0.00106	CbGpPWpGaD
Asenapine—HRH2—Signaling Pathways—KITLG—testicular cancer	8.86e-05	0.000985	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	8.71e-05	0.000969	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—HPGDS—testicular cancer	8.65e-05	0.000962	CbGpPWpGaD
Asenapine—HTR1E—Signaling Pathways—FGFR3—testicular cancer	7.39e-05	0.000822	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—H2AFZ—testicular cancer	7.38e-05	0.000821	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—H2AFZ—testicular cancer	7.37e-05	0.00082	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—STK11—testicular cancer	7.34e-05	0.000816	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—STK11—testicular cancer	7.33e-05	0.000815	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—H2AFZ—testicular cancer	7.33e-05	0.000815	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—STK11—testicular cancer	7.28e-05	0.00081	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—H2AFZ—testicular cancer	7.17e-05	0.000798	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—STK11—testicular cancer	7.13e-05	0.000793	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—H2AFZ—testicular cancer	7.06e-05	0.000785	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—HPGDS—testicular cancer	7.03e-05	0.000782	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—STK11—testicular cancer	7.02e-05	0.00078	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—KITLG—testicular cancer	6.79e-05	0.000755	CbGpPWpGaD
Asenapine—HTR1E—Signaling Pathways—KIT—testicular cancer	6.78e-05	0.000754	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—KITLG—testicular cancer	6.78e-05	0.000754	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—KITLG—testicular cancer	6.74e-05	0.000749	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—H2AFZ—testicular cancer	6.74e-05	0.000749	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—STK11—testicular cancer	6.7e-05	0.000745	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—KITLG—testicular cancer	6.6e-05	0.000734	CbGpPWpGaD
Asenapine—HRH2—Signaling Pathways—FGFR3—testicular cancer	6.58e-05	0.000732	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—KITLG—testicular cancer	6.49e-05	0.000722	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—H2AFZ—testicular cancer	6.36e-05	0.000707	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—STK11—testicular cancer	6.32e-05	0.000703	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—STK11—testicular cancer	6.29e-05	0.000699	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—H2AFZ—testicular cancer	6.27e-05	0.000697	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—STK11—testicular cancer	6.23e-05	0.000693	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—KITLG—testicular cancer	6.2e-05	0.000689	CbGpPWpGaD
Asenapine—HRH2—Signaling Pathways—KIT—testicular cancer	6.04e-05	0.000672	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—KITLG—testicular cancer	5.85e-05	0.00065	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—KITLG—testicular cancer	5.77e-05	0.000641	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—H2AFZ—testicular cancer	5.71e-05	0.000635	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—STK11—testicular cancer	5.68e-05	0.000632	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—H2AFZ—testicular cancer	5.66e-05	0.000629	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—STK11—testicular cancer	5.63e-05	0.000626	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—H2AFZ—testicular cancer	5.59e-05	0.000621	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—STK11—testicular cancer	5.56e-05	0.000618	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—H2AFZ—testicular cancer	5.46e-05	0.000608	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—H2AFZ—testicular cancer	5.44e-05	0.000605	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—STK11—testicular cancer	5.43e-05	0.000604	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—STK11—testicular cancer	5.41e-05	0.000601	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—H2AFZ—testicular cancer	5.29e-05	0.000588	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—STK11—testicular cancer	5.26e-05	0.000585	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—KITLG—testicular cancer	5.26e-05	0.000584	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—KITLG—testicular cancer	5.21e-05	0.000579	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—KITLG—testicular cancer	5.14e-05	0.000572	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—STK11—testicular cancer	5.11e-05	0.000568	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—FGFR3—testicular cancer	5.05e-05	0.000561	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—FGFR3—testicular cancer	5.04e-05	0.000561	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—KITLG—testicular cancer	5.03e-05	0.000559	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—FGFR3—testicular cancer	5.01e-05	0.000557	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—KITLG—testicular cancer	5e-05	0.000556	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—FGFR3—testicular cancer	4.9e-05	0.000545	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—KITLG—testicular cancer	4.86e-05	0.000541	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—FGFR3—testicular cancer	4.83e-05	0.000537	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—H2AFZ—testicular cancer	4.8e-05	0.000534	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—STK11—testicular cancer	4.77e-05	0.00053	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—H2AFZ—testicular cancer	4.72e-05	0.000525	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—H2AFZ—testicular cancer	4.71e-05	0.000524	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—STK11—testicular cancer	4.69e-05	0.000522	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—STK11—testicular cancer	4.68e-05	0.000521	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—KIT—testicular cancer	4.63e-05	0.000515	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—KIT—testicular cancer	4.63e-05	0.000515	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—H2AFZ—testicular cancer	4.62e-05	0.000514	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—FGFR3—testicular cancer	4.61e-05	0.000512	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—KIT—testicular cancer	4.6e-05	0.000511	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—STK11—testicular cancer	4.6e-05	0.000511	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—HPGDS—testicular cancer	4.58e-05	0.000509	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—KIT—testicular cancer	4.5e-05	0.000501	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—KIT—testicular cancer	4.43e-05	0.000493	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—KITLG—testicular cancer	4.41e-05	0.000491	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—FGFR3—testicular cancer	4.35e-05	0.000483	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—KITLG—testicular cancer	4.34e-05	0.000483	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—KITLG—testicular cancer	4.33e-05	0.000482	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—H2AFZ—testicular cancer	4.3e-05	0.000478	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—FGFR3—testicular cancer	4.29e-05	0.000477	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—STK11—testicular cancer	4.27e-05	0.000475	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—KITLG—testicular cancer	4.25e-05	0.000473	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—KIT—testicular cancer	4.23e-05	0.00047	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—KIT—testicular cancer	3.99e-05	0.000444	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—KITLG—testicular cancer	3.95e-05	0.000439	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—KIT—testicular cancer	3.94e-05	0.000438	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—FGFR3—testicular cancer	3.91e-05	0.000434	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—HPGDS—testicular cancer	3.88e-05	0.000431	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—FGFR3—testicular cancer	3.87e-05	0.00043	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—FGFR3—testicular cancer	3.82e-05	0.000425	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—FGFR3—testicular cancer	3.74e-05	0.000415	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—FGFR3—testicular cancer	3.72e-05	0.000413	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—FGFR3—testicular cancer	3.62e-05	0.000402	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—KIT—testicular cancer	3.59e-05	0.000399	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—KIT—testicular cancer	3.55e-05	0.000395	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—KIT—testicular cancer	3.51e-05	0.00039	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—KIT—testicular cancer	3.43e-05	0.000381	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—KIT—testicular cancer	3.41e-05	0.000379	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—STK11—testicular cancer	3.33e-05	0.00037	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—KIT—testicular cancer	3.32e-05	0.000369	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—FGFR3—testicular cancer	3.28e-05	0.000365	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—FGFR3—testicular cancer	3.23e-05	0.000359	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—FGFR3—testicular cancer	3.22e-05	0.000358	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—FGFR3—testicular cancer	3.16e-05	0.000351	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—KIT—testicular cancer	3.01e-05	0.000335	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—HPGDS—testicular cancer	2.99e-05	0.000333	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—KIT—testicular cancer	2.96e-05	0.00033	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—KIT—testicular cancer	2.96e-05	0.000329	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—FGFR3—testicular cancer	2.94e-05	0.000327	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—KIT—testicular cancer	2.9e-05	0.000323	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—STK11—testicular cancer	2.82e-05	0.000313	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—KIT—testicular cancer	2.7e-05	0.0003	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—STK11—testicular cancer	2.18e-05	0.000242	CbGpPWpGaD
